Loading...
Loading...
Alkermes
ALKS today announced new developments related to its
late-stage product candidates in its proprietary central nervous system
(CNS) pipeline. The company unveiled aripiprazole lauroxil two-month, a
new product candidate addition to its portfolio of atypical
antipsychotics for the treatment of schizophrenia. If approved,
aripiprazole lauroxil two-month would be the first and only long-acting
atypical antipsychotic medication dosed every two months. This new
two-month product candidate is designed to provide physicians and
patients with an even longer dosing option than the once-monthly
formulation of aripiprazole lauroxil, which is currently completing the
phase 3 study, with topline results expected in the first half of 2014.
In addition, Alkermes provided details regarding its pivotal phase 3
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in